CJC-1295 (No DAC) / Mod GRF (1-29)
Short-acting GHRH analogue — despite the name, a different molecule from trial CJC-1295.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About CJC-1295 (No DAC) / Mod GRF (1-29)
Sold as "CJC-1295 no DAC," this is tetrasubstituted GHRH(1-29) — commonly called Modified GRF (1-29). The name is a research-market misnomer: the CJC-1295 studied in human trials is defined by its Drug Affinity Complex (DAC), which is exactly what this version lacks. Without DAC there is no albumin binding, so the half-life is roughly 30 minutes instead of 6–8 days, and the dosing pattern is completely different (multiple small daily doses rather than one or two per week). Its parent sequence, GHRH(1-29), is the same active fragment as sermorelin, which was an approved drug (Geref); the specific tetrasubstituted analogue sold under the CJC-1295 name has no published human trials of its own.
Key Benefits
- Stimulates a short, GHRH-driven GH pulse
- Short half-life allows dose timing around natural GH pulses
- Frequently paired with a ghrelin-receptor agonist such as Ipamorelin
- Parent sequence GHRH(1-29) is well characterised (as sermorelin)
Set a goal (top of the page) to see how CJC-1295 (No DAC) / Mod GRF (1-29) scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Injection site irritation
- Flushing
- Headache
- Transient dizziness
- Water retention
Legal & Regulatory Status
Research use only. Not FDA-approved, and not the compound that entered human trials as CJC-1295 — no published human trials exist for this tetrasubstituted GHRH(1-29) analogue specifically.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- Trial CJC-1295 (with DAC) — establishes that DAC defines the studied molecule (PMID 16352683)
- GHRH(1-29)/sermorelin — the parent sequence, in a diagnostic review (PMC6941588)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.